Drug Profile
Research programme: biosimilars - UMN Pharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator UMN Pharma
- Class Recombinant proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Japan (Parenteral)